Key Takeaways
- UnityAI raised $8.5 million in a Series A round in March 2026, bringing the company’s total capital raised to $15 million since its founding.
- The funding round was led by Third Prime, with participation from Nashville Capital Network, Whistler Capital Partners, Max Ventures, and Company Ventures.
- The company’s agentic AI platform currently manages more than 300,000 patient interactions each month, supporting operations across hundreds of healthcare sites nationwide.
- Operational efficiency improvements have been significant, with the platform completing 90% of scheduling tasks without human involvement.
- Escalation rates remain below 6%, indicating strong automation performance and reduced reliance on manual support teams.
- Healthcare providers using the platform have reported a 25% increase in converted patient referrals, demonstrating measurable operational and revenue impact.
Quick Recap
UnityAI, a Nashville, Tennessee-based agentic AI company building an autonomous workforce for healthcare operations, has officially closed an $8.5 million Series A funding round, according to an announcement published on March 4, 2026. The round was led by Third Prime and brings the company’s total capital raised to $15 million. The funding will be used to scale go-to-market execution and extend the company’s AI-powered operational capabilities across specialty care, dental, and value-based care providers.
Architecture Behind UnityAI
UnityAI is not a conventional scheduling chatbot. The company deploys what it calls an “agentic AI workforce,” a suite of specialized autonomous agents that actively execute multi-step operational tasks without constant human oversight. The platform operates across three core pillars: UNITY:Patient for patient-facing engagement via voice and text, UNITY:Team for staff coverage and shift coordination, and UNITY:Practice for predictive operational optimization.
The company’s AI agents integrate deeply with Electronic Health Records (EHR), carry clinical context awareness, and maintain full traceability across every automated interaction. Unlike tools that merely surface information, UnityAI’s agents actively communicate with patients to confirm appointments, coordinate referrals, handle follow-ups for no-shows, and complete outreach tasks end-to-end.
CEO and co-founder Edmund Jackson framed the company’s mission this way: “What holds healthcare back rarely happens inside the exam room, but instead is everything that determines whether a patient gets there at all.” The platform has already broken out of the “pilot purgatory” that traps many healthcare AI vendors, operating at nationwide scale with large specialty groups such as Tennessee Oncology and behavioral health provider Peregrine Health. Customers report a 4.5x ROI, a 25% increase in appointments, and a 29% gain in scheduler productivity.
The company raised a $4 million seed round back in 2024 led by Max Ventures, before expanding its product suite in late 2025 to include voice agents for outpatient scheduling and follow-up. The Series A capital will now fund broader commercial expansion rather than pure product development, signaling that the company views its technology as proven and market-ready.
Agentic AI Wave in Healthcare
UnityAI’s raise arrives at a moment when investor conviction in agentic healthcare AI has never been higher. The U.S. healthcare system faces a structural staffing crisis, with administrative burdens consuming an enormous share of clinical resources. AI-powered automation at the “last mile” of patient engagement, whether that means confirming an oncology appointment or coordinating a referral, is increasingly seen as the most direct lever for operational relief.
The broader funding environment validates this thesis. Hyro raised $45 million in growth funding in October 2025, doubling its valuation and bringing total funding to $95 million. Assort Health followed with a $76 million Series B led by Lightspeed Venture Partners, pushing its total raise to $102 million. Both companies target overlapping use cases around patient scheduling and voice-based engagement, yet each takes a different technical and go-to-market approach.
UnityAI differentiates itself in three specific ways. First, its automation scope extends beyond patient-facing voice to include staffing coordination, making it a broader operational platform rather than a point solution. Second, its roots in HCA Healthcare give it credibility and access inside complex, high-acuity environments. Third, it targets mid-sized specialty groups and multi-site operators that are underserved by enterprise AI tools.
Competitive Landscape
| Feature / Metric | UnityAI | Hyro | Assort Health |
| Total Funding Raised | $15M | $95M | $102M |
| Latest Round | $8.5M Series A (2026) | $45M Growth Round (2025) | $76M Series B (2025) |
| Lead Investor | Third Prime | Healthier Capital | Lightspeed Venture Partners |
| Core Use Case | End-to-end ops: scheduling, staffing, referrals, outreach | Voice AI agents for patient access and call center automation | Voice agents for specialty practice patient communication |
| Monthly Scale | 300,000+ patient interactions | 30M+ patient engagements across 45+ health systems | Focused on specialty practices; scaling post-Series B |
| EHR Integration | Deep EHR integration with clinical context | Integrated with health system workflows | Integrates with practice management systems |
| Agentic Capabilities | Full ops automation: voice, staffing, outreach, predictive | AI agents for scheduling, prescriptions, billing | Specialty-specific agents across voice, text, web |
| Primary Target Market | Specialty care groups, dental, value-based care, mid-market | Large health systems and hospitals | Small to mid-sized specialty practices |
| HQ | Nashville, TN | New York, NY | San Francisco, CA |
UnityAI leads among Series A-stage peers in operational breadth, covering staffing and multi-site orchestration that voice-only competitors do not address. Hyro commands scale and enterprise reach with 30 million monthly engagements across major health systems, while Assort Health wins on specialty depth and investor valuation momentum at $750 million post-Series B.
Bayelsa Watch’s Takeaway
I want to be direct here: I think this is a genuinely interesting deal, even if the headline number is modest compared to the nine-figure rounds flying around healthcare AI right now. In my experience covering agentic AI funding, the companies that get to a $45M or $76M round are almost always the ones that got their Series A right. UnityAI, in my read, has done exactly that.
They are not chasing a broad addressable market with vague product promises. They have 300,000 monthly interactions on the books, real enterprise clients like Tennessee Oncology, and unit economics (4.5x ROI, 90% task completion without human escalation) that any growth investor would pay attention to. That is not pilot-stage software. That is a company that has genuinely earned its next round.
I generally prefer backing teams that came from the problem itself, and UnityAI’s founding team coming out of HCA Healthcare matters a lot here. Healthcare AI is a graveyard of well-funded companies that failed because they did not understand clinical workflows. This team does.
